Bacterial
Anything that destroys bacteria or suppresses their growth or their ability to reproduce. Heat, chemicals such as chlorine, and antibiotic drugs all have antibacterial properties. Many antibacterial products for cleaning and handwashing are sold today. Such products do not reduce the risk for symptoms of viral infectious diseases in otherwise healthy persons. This does not preclude the potential contribution of antibacterial products to reducing symptoms of bacterial diseases in the home.
All Product Categories
-
Bacterial Inhibitors
(7510)
View all products
-
Bacterial Agonists
(3)
View all products
-
Bacterial Antagonists
(9)
View all products
-
Bacterial Activators
(23)
View all products
-
Bacterial Modulators
(27)
View all products
-
Bacterial Chemicals
(2)
View all products
-
Bacterial Inducers
(7)
View all products
-
Bacterial Controls
(14)
View all products
-
Bacterial Substrates
(2)
View all products
-
Bacterial Ligand
(1)
View all products
-
Bacterial Related Products (8837)
Related Products (8837)
-
Antibodies (14)
-
Related Compound Screening Libraries (1)
-
Gatifloxacin sesquihydrate (Standard)
0 ImagesCat. No.: HY-10581CRCAS No.: 180200-66-2Synonyms: AM-1155 sesquihydrate (Standard); BMS-206584 sesquihydrate (Standard); PD135432 sesquihydrate (Standard)Gatifloxacin (sesquihydrate) (Standard) is the analytical standard of Gatifloxacin (sesquihydrate). This product is intended for research and analytical applications. Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml). Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis?in vivo.
-
GKL003
0 ImagesCat. No.: HY-102072CAS No.: 1445801-61-5GKL003 is a bacterial transcription inhibitor that targets the RNAP-σ interaction interface, with a Ki of 5.79 nM. GKL003 specifically binds to the RNAP β' clamp helix region at the σA factor binding site, blocks the formation of RNAP holoenzyme, and inhibits the formation of bacterial transcription initiation complexes. GKL003 inhibits the growth of both Gram-positive and Gram-negative bacterial cells, and also exhibits activity against drug-resistant strains.
-
Antimicrobial agent-39
0 ImagesCat. No.: HY-170993Antimicrobial agent-39 (Compound 8i) is an antibiotic that targets 50S ribosomal subunit and inhibits bacterial protein synthesis. Antimicrobial agent-39 disrupts bacterial cell membranes, leads to leakage of cell contents, thereby exhibiting board-spectrum actibacterial activity. Antimicrobial agent-39 targets organic cation transporters (OCTs), accumulates in infected kidneys, thereby ameliorating pyelonephritis in mouse models.
-
BV02 (Standard)
0 ImagesCat. No.: HY-101985RCAS No.: 292870-53-2BV02 (Standard) is the analytical standard of BV02 (HY-101985). This product is intended for research and analytical applications. BV02 is a 14-3-3 inhibitor and an antibacterial agent. BV02 enhances the cleavage of PARP and caspase-3. BV02 induces Apoptosis, Autophagy, and enhances Akt activation. BV02 has anti-B. melitensis infection and epilepsy-promoting effects. BV02 can also be used in colitis research.
-
Granaticin
0 ImagesCat. No.: HY-119968CAS No.: 19879-06-2Synonyms: Granaticin A; LitmomycinGranaticin A inhibits the initial stage of RNA biosynthesis, has anti-Gram-positive bacteria, Mycobacterium (weak) and Vaginal trichomonas activity, but also can inhibit tumor cells.
-
Demycarosyl platenomycin
0 ImagesCat. No.: HY-N14732CAS No.: 52044-89-0Synonyms: DM-PLMDemycarosylplatenomycin (DM-PLM) is an antibiotic with weak activity against Gram-positive bacteria.
-
Pneumocandin B2
0 ImagesCat. No.: HY-N14468CAS No.: 138530-80-0Pneumocandin B2 is a lipopeptide antibiotic. Pneumocandin B2 has a strong anti-Candida effect. Pneumocandin B2 has the effect of inhibiting the synthesis of 1,3 early-glucan in vitro, with an IC50 of 0.07-0.5 μg/mL.
-
Bithionol (Standard)
0 ImagesBithionol (Standard) is the analytical standard of Bithionol. This product is intended for research and analytical applications. Bithionol is an antibacterial, anthelmintic, and algaecide agent. Bithionol is also a potent inhibitor of soluble adenylyl cyclase through binding to the allosteric activator site (IC50: 4 μM).
-
Cefsulodin sodium (Standard)
0 ImagesCat. No.: HY-13588RCAS No.: 52152-93-9Synonyms: SCE-129 sodium (Standard)Cefsulodin (sodium) (Standard) is the analytical standard of Cefsulodin (sodium). This product is intended for research and analytical applications. Cefsulodin (SCE-129) sodium is a third generation β lactam antibiotic and member of the cephems subgroup of antibiotics. Cefsulodin sodium inhibits cell wall synthesis by competitively inhibiting penicillin binding protein (PBP) cross-linking and transpeptidation of peptidogly. Cefsulodin sodium is a potent tyrosine phosphatase inhibitor against mPTPB, a virulent phosphatase from Mycobacterium tuberculosis, with an IC50 value of 16 μM.
-
Mtb-IN-12
0 ImagesCat. No.: HY-175262Mtb-IN-12 (Compound 5m) is a dual-target inhibitor that can target the CYP125 (KD: 40 nM; KI: 0.1 μM) and CYP142 (KD: 160 nM; KI: 0.05 μM) enzymes of Mycobacterium tuberculosis. Mtb-IN-12 exhibits good inhibitory activity against both drug-sensitive strains and multidrug-resistant tuberculosis strains, with low toxicity to macrophages. Mtb-IN-12 can be used in the research of anti-tuberculosis drugs.
-
Rifabutin-vonoprazan conjugate 1
0 ImagesCat. No.: HY-181038Rifabutin-vonoprazan conjugate 1 is an orally active acid-responsive bifunctional molecule. Rifabutin-vonoprazan conjugate 1 exhibits anti-Helicobacter pylori activity (MIC ≤ 0.125 μg/mL) and acid-suppressive effects (acid inhibition rate > 85% at a dose of 2 mg/kg). Rifabutin-vonoprazan conjugate 1 also demonstrates anti-ulcer activity. Rifabutin-vonoprazan conjugate 1 can be used in research related to Helicobacter pylori infection and gastric ulcer.
-
13-Deoxycarminomycin
0 ImagesCat. No.: HY-126954CAS No.: 76034-18-913-Deoxycarminomycin is an antibiotic with antibacterial activity. 13-Deoxycarminomycin also exhibits cytotoxicity against tumor cells such as HeLa and P388, and can play an anti-tumor role.
-
Citreamicin β
0 ImagesCat. No.: HY-N14129CAS No.: 128999-30-4Citreamicin β has anti-Gram-positive aerobic and anaerobic bacterial activities.
-
Cedarmycin B
0 ImagesCat. No.: HY-N14012CAS No.: 363624-70-8Cedarmycin B has activities against Candida, Cryptococcus neoforme and Aspergillus fumigatus, with the MIC values of 12.5-50 μg/mL.
-
Octacosamicin B
0 ImagesCat. No.: HY-N14527CAS No.: 122005-24-7Octacosamicin B has the function of resisting bacterium, yeast, and filamentous fungus, but the function of resisting bacterium is weak.
-
Antibacterial agent 303
0 ImagesCat. No.: HY-W264454CAS No.: 5342-95-0Antibacterial agent 303 (compound 3) is an antibacterial agent exhibiting potent antibacterial activity against MDR strains, with MICs of 10 and 100 µg/mL against Pseudomonas aeruginosa MDR1 and Staphylococcus aureus MDR strains, respectively. Antibacterial agent 303 displays strong binding affinities to E. coli DNA gyrase and Candida albicans lanosterol 14α-demethylase. Antibacterial agent 303 can be used for drug-resistant infections research.
-
Furazolidone (Standard)
0 ImagesFurazolidone (Standard) is the analytical standard of Furazolidone. This product is intended for research and analytical applications. Furazolidone is a nitrofuran derivative with antiprotozoal and antibacterial activity. It inhibits AML1-ETO transformed cells with an IC50 of 12.7 μM.
-
RhlR agonist-1
0 ImagesCat. No.: HY-133161CAS No.: 1061591-41-0RhlR agonist-1 is a N-acylated L-homoserine lactone and is a selective quorum sensing receptor RhlR agonist. RhlR agonist-1 can be used for the research of bacterial infections.
-
CAP 3
0 ImagesCat. No.: HY-115693CAS No.: 2292123-03-4CAP 3 is a cholic acid-peptide conjugate (CAP) antimicrobial agent. CAP 3 effectively inhibits Gram-negative bacteria, with MIC99 (minimum inhibitory concentration for 99% bacterial killing) values of 8 μM, 16 μM, and 16 μM against E. coli, Klebsiella pneumoniae and Acinetobacter baumannii, respectively. CAP 3 exerts its antibacterial effects by disrupting the structural integrity of the bacterial lipopolysaccharide (LPS) outer membrane. CAP 3 rapidly kills bacteria, inhibits biofilm formation, and effectively combats drug-resistant strains and persistent bacterial infections.
